non-clinical drug development blog posts

28 January, 2019

What you need to know about preclinical species selection

By Kirsty Harper

Traditionally, the selection of relevant species for non-clinical studies, as part of the preclinical drug development phase, has been a fairly straightforward process. This consists of new drugs assessed in two species, typically the rat and dog.  However, with the introduction of biologics, preclinical species selection has become much more of a case by case process, and as a result target-specific pharmacology plays a critical role, for both biologics and increasingly small molecule drugs.

+ Read more
 

03 October, 2018

How to get the most out of your preclinical CRO

By Freddie Campbell

Many industry observers have said there's no such thing as a straightforward pharmaceutical development program anymore. Rising costs, high competition, novel therapeutic targets with complex biology and an increase in regulations are all factors that contribute to the challenges of progressing drugs to the market. 

+ Read more
 

01 August, 2018

6 challenges to overcome in preclinical drug development

By Freddie Campbell

Panel-and-speakers at Modern Drug Development RoadshowBringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.

We recently held a roadshow in Cambridge and London, UK, to discuss the challenges in designing and executing a non-clinical development program, as part of the preclinical phase, as well as how to effectively overcome these challenges. At 'Modern Drug Development - keeping your non-clinical program on track', delegates heard from:

- Dr. Robert Turcan, Head of Regulatory Affairs and Program Management, Envigo, on: "Drug Development - expect the best, plan for the worst, and prepare to be surprised!", which focused on the development of small molecules

- Dr. Kirsty Harper, Head of Biologics, Envigo, on: "Identifying, addressing and smoothing the bumps in the road to successful non-clinical development", relating to the development of biologics.

There was also a panel of experts who co-presented and answered questions from delegates.

In this post, you'll discover the six main take home messages from the roadshow.

+ Read more